Evidence map›Paper›PMID 10760259›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2000

Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task.

A Karlstrom, G Zhong, C Rader, N A Larsen, A Heine, R Fuller, B List, F Tanaka, I A Wilson, C F Barbas and 1 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Chemically programmed antibodies.Trends in biotechnology · 2014
    Review
  6. Article
  7. Instant immunity through chemically programmable vaccination and covalent self-assembly.Proceedings of the National Academy of Sciences of the United States of America · 2009
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

A KarlstromThe Skaggs Institute for Chemical Biology and the Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
G Zhong
C Rader
N A Larsen
A Heine
R Fuller
B List
F Tanaka
I A Wilson
C F Barbas
R A Lerner

Funding

TUMORICIDAL ACTIVITY OF HOST COMPLEMENTP01CA027489 · NCI · SCRIPPS RESEARCH INSTITUTE · PI LERNER, RICHARD ALAN · 1985 to 2004
$7.7M
NCI NIH HHS CA27489NCI NIH HHS P01 CA027489
6 · The paper itself

Abstract

Catalytic aldolase antibodies generated by immunization with two different, but structurally related, beta-diketone haptens were cloned and sequenced to study similarities and differences between independently evolved catalysts. Kinetic and sequence analysis coupled with mutagenesis, structural, and modeling studies reveal that the defining event in the evolution of these catalysts was a somatic mutation that placed a lysine residue in a deep, yet otherwise unrefined, hydrophobic pocket. We suggest that covalent chemistries may be as readily selected from the immune repertoire as the traditional noncovalent interactions that have formed the basis of immunochemistry until this time. Further, we believe that these experiments recapitulate the defining events in the evolution of nature's enzymes, particularly as they relate to chemical mechanism, catalytic promiscuity, and gene duplication.

Indexed as

Evolution, MolecularAmino Acid SequenceAnimalsAntibodies, CatalyticBinding SitesCell LineCloning, MolecularFructose-Bisphosphate AldolaseMiceModels, MolecularMolecular Sequence DataMutagenesis, Site-DirectedProtein ConformationSequence Homology, Amino AcidAntibodies, CatalyticFructose-Bisphosphate Aldolase

Identifiers

PMID10760259
PMCPMC18110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.